Table 2.
Validation in the independent WHI-HT dataset of metabolites associations with future CHD discovered in the WHI-OS metabolites.
| Metabolite | WHI-HT Adjusted for matching* |
WHI-HT Adjusted for risk factors† |
||
|---|---|---|---|---|
| Odds Ratio‡ | P-value§ | Odds Ratio‡ | P-value§ | |
| C34:2 hydroxy-PC | 1.83 (1.54, 2.17) | 5.4E-13 | 1.76 (1.47, 2.10) | 2.5E-10 |
| C36:4 hydroxy-PC | 1.66 (1.39, 1.99) | 2.4E-09 | 1.56 (1.30, 1.87) | 7.0E-07 |
| 15-HETE | 1.73 (1.44, 2.07) | 2.3E-10 | 1.65 (1.36, 1.99) | 5.6E-08 |
| 5-HETE | 1.71 (1.43, 2.04) | 3.0E-10 | 1.65 (1.37, 1.99) | 2.6E-08 |
| 11-HETE | 1.68 (1.41, 2.00) | 9.0E-10 | 1.64 (1.36, 1.97) | 4.3E-08 |
| 12-HETE | 1.64 (1.38, 1.95) | 3.9E-09 | ||
| glutamate | 1.64 (1.38, 1.95) | 5.5E-09 | 1.50 (1.25, 1.80) | 8.3E-06 |
| glutamine | 0.61 (0.50, 0.73) | 1.4E-08 | 0.67 (0.55, 0.82) | 2.5E-05 |
| asparagine | 0.75 (0.64, 0.88) | 4.2E-04 | ||
| CMP | 1.38 (1.17, 1.63) | 1.1E-04 | 1.33 (1.11, 1.59) | 1.4E-03 |
| uracil | 0.80 (0.68, 0.94) | 6.5E-03 | ||
| xanthosine | 0.80 (0.68, 0.95) | 7.5E-03 | ||
| glucose | 1.42 (1.19, 1.69) | 3.4E-05 | ||
| sucrose | 1.40 (1.18, 1.65) | 7.2E-05 | ||
| sorbitol | 1.28 (1.08, 1.51) | 3.4E-03 | ||
| 2-hydroxyglutarate | 1.45 (1.22, 1.72) | 1.0E-05 | ||
| fumarate/maleate | 1.22 (1.03, 1.44) | 2.1E-02 | ||
| isocitrate | 1.21 (1.02, 1.42) | 2.4E-02 | ||
| C50:0 TAG | 1.37 (1.16, 1.61) | 1.4E-04 | ||
| C50:1 TAG | 1.34 (1.14, 1.58) | 3.6E-04 | ||
| C52:0 TAG | 1.42 (1.20, 1.67) | 2.5E-05 | ||
| C52:1 TAG | 1.38 (1.17, 1.63) | 8.1E-05 | ||
| C52:2 TAG | 1.32 (1.12, 1.55) | 7.8E-04 | ||
| C54:1 TAG | 1.34 (1.14, 1.58) | 3.3E-04 | ||
| C54:2 TAG | 1.36 (1.15, 1.60) | 2.0E-04 | ||
| C54:3 TAG | 1.25 (1.06, 1.47) | 6.7E-03 | ||
| C56:2 TAG | 1.34 (1.14, 1.59) | 3.4E-04 | ||
| C56:3 TAG | 1.23 (1.05, 1.45) | 1.2E-02 | ||
| C34:0 DAG | 1.26 (1.06, 1.49) | 6.5E-03 | ||
| C34:1 DAG | 1.40 (1.18, 1.65) | 5.9E-05 | ||
| C36:1 DAG | 1.41 (1.19, 1.67) | 3.9E-05 | ||
| C36:2 DAG | 1.31 (1.11, 1.54) | 1.3E-03 | ||
| C40:10 PC | 0.82 (0.70, 0.97) | 1.8E-02 | ||
*
adjusted for baseline age, race/ethnicity, hysterectomy status, and enrollment window
†
adjusted for baseline age, race/ethnicity, hysterectomy status, enrollment window, aspirin use, statin use, anti-hyperglycemic use, anti-hypertensive use, smoking, systolic blood pressure, diabetes, total and HDL cholesterol.
‡
odds ratios are per 1 standard deviation of log transformed values
§
Nominal p-values presented, cutoff for validation was nominal p<0.025 and FDR adjusted p-value less than 0.05